Results 221 to 230 of about 373,942 (290)

An investigation of the quality of Syrian health insurance services via the SERVQUAL approach: a cross-sectional study. [PDF]

Cost Eff Resour Alloc
Mouselli S, Allahham L, Al Ahdab S.
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Employee retention for subscribers with and without an obesity diagnosis in self-insured employer health plans: A claims-based analysis. [PDF]

J Manag Care Spec Pharm
Naber J, Kuester M, Chmura L, Vallarino C, Ward J, Tian H, Dell S, Xue J.   +7 more
europepmc   +1 more source

Measuring the Impact: Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth With Axial Disease

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes (PROs) in youth with axial juvenile spondyloarthritis (axJSpA) initiating tumor necrosis factor inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source

Sociodemographic disparities in Hepatitis C care utilization and testing in the United States. [PDF]

Commun Med (Lond)
Buckholz AP, Ying X, Liu Y, McSteen B, Blocker O, Unruh M, Mallick H, Brown RS.   +7 more
europepmc   +1 more source

Coverage generosity of novel anti‐rheumatic drugs in Medicare Advantage and stand‐alone Part D plans

Arthritis &Rheumatology, Accepted Article.
Objective To examine coverage of self‐administered disease‐modifying anti‐rheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022‐2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T‐cell co‐stimulatory modulator, Interleukin‐6 ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

Cesarean Section Rates and Mobile Health's Role in Equitable Access to Prenatal Care. [PDF]

Int J Environ Res Public Health
Person-Rennell N, Rivers P, Hollister J, Dinsmore A, Bratsch N, Ortiz J, Rundell K, Lutrick K.   +7 more
europepmc   +1 more source

Validation of International Classification of Diseases (ICD) code‐based case definitions of immune checkpoint inhibitor associated inflammatory arthritis from administrative health data

Arthritis &Rheumatology, Accepted Article.
Background Immune checkpoint inhibitors (ICIs) for cancer can lead to immune‐related adverse events, including ICI‐associated inflammatory arthritis (ICI‐IA). There are no validated International Classification of Diseases (ICD) code–based case definitions for ICI‐IA.
Manar Elsayed, Zoe Hsu, Finlay A. McAlister, William D. Leslie, Lisa M. Lix, Sasha Bernatsky, Suzanne N Morin, Michelle M Graham, Aurore Fifi‐Mah, Shahin Jamal, Janet Roberts, Carrie Ye   +11 more
wiley   +1 more source

Cardiac Rehabilitation Trends Among Commercially Insured Adults in the United States, 2017-2023. [PDF]

Circ Cardiovasc Qual Outcomes
Pollack LM, Kompaniyets L, Chang A, Thompson MP, Keteyian SJ, Stolp H, Wall HK, Sperling LS, Jackson SL.   +8 more
europepmc   +1 more source

ANK1 and EPB41 Variants and The Risk of Steroid‐Induced Osteonecrosis

Arthritis &Rheumatology, Accepted Article.
Objective Steroid‐induced osteonecrosis of the femoral head (SONFH) is a refractory skeletal disorder influenced by genetic and environmental factors. However, conclusive pathogenic genetic evidence remains elusive due to the limited exploration of rare damaging variants. In this study, we aimed to identify rare variants associated with SONFH.
Shengbao Chen, Xianmin Zhu, Zhongzhong Chen, Wei Chen, Hussam Alkaissi, Zeng Zhang, Yun Gao, Junhui Yin, Xiangtian Yu, Qiong Fu, Youshui Gao, Zhenzhong Zhu, Qianying Cai, Pengwei Zhang, Weibin Chen, Xin Zhao, Xiaojin Wu, Karel Pacak, Dongxu Jin, Chunde Bao, Zhengping Zhuang, Changqing Zhang   +21 more
wiley   +1 more source